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Objective: Desmopressin releases tissue-type plasminogen activator, which aug-
ments cardiopulmonary bypass–associated hyperfibrinolysis, causing excessive
bleeding. Combined use of desmopressin with prior administration of the antifibri-
nolytic drug tranexamic acid may decrease fibrinolytic activity and might improve
postoperative hemostasis.
Methods: This prospective randomized study was carried out with 100 patients
undergoing coronary artery bypass operations between April 1999 and November
2000 in Gülhane Military Medical Academy. Patients were divided into 2 groups.
Desmopressin (0.3 µg/kg) was administrated just after cardiopulmonary bypass and
after protamine infusion in group 1 (n = 50). Both desmopressin and tranexamic
acid (before the skin incision at a loading dose of 10 mg/kg over 30 minutes and
followed by 12 hours of 1 mg·kg–1·h–1) were administrated in group 2 (n = 50).
Results: Significantly less drainage was noted in group 2 (1010 ± 49.9 mL vs 623
± 41.3 mL, P = .0001). Packed red blood cells were transfused at 2.1 ± 0.5 units per
patient in group 1 versus 0.9 ± 0.3 units in group 2 (P = .0001). Fresh frozen plasma
was transfused at 1.84 ± 0.17 units per patient in group 1 versus 0.76 ± 0.14 units
in group 2 (P = .0001). Only 24% of patients in group 2 required donor blood or
blood products compared with 74% of those in the isolated desmopressin group
(group 1, P = .00001). Group 1 and group 2 findings were as follows: postoperative
fibrinogen, 113 ± 56.3 mg/dL versus 167 ± 45.8 mg/dL (P = .0001); fibrin split
product, 21.2 ± 2.3 ng/mL versus 13.5 ± 3.4 ng/mL (P = .0001); and postoperative
hemoglobin level, 7.6 ± 1.2 g/dL versus 9.1 ± 1.2 g/dL (P = .0001).
Conclusion: Tranexamic acid administration significantly reduces desmopressin
and bypass-induced hyperfibrinolysis. Combined use of tranexamic acid and
desmopressin decreases both postoperative blood loss and transfusion requirement.
Excessive bleeding after cardiac operation is a major concern for car-diac surgeons. It has been reported in 5% to 25% of patients under-going cardiopulmonary bypass (CPB). However, only 3% to 5% ofall patients undergoing cardiac operations require reoperation forbleeding.1 This figure becomes more important in view of theincreasing number of reoperations and emergency surgical proce-
dures during which patients are still under the effect of antiplatelet or fibrinolytic
agents.2 Hemostatic drugs are among the measures available to decrease bleeding
and transfusion. Aprotinin,3 desmopressin,4,5 and lysine-analogue antifibrinolytic
preparations, such as ε-aminocaproic acid2 and tranexamic acid,6 may provide salu-
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tary hemostatic effects. Desmopressin acetate has been
found to shorten bleeding time, thus reducing blood loss. It
acts by inducing the release of von Willebrand factor from
the endothelial cells.7 Desmopressin also transiently
releases tissue-type plasminogen activator from endothelial
cells.8 Plasminogen activator could augment a CPB-associ-
ated fibrinolytic state.9 Augmented fibrinolysis induced by
release of tissue plasminogen activator might negate a salu-
tary effect of desmopressin. If so, then prior treatment with
a potent antifibrinolytic agent should unmask a desmo-
pressin-mediated decrease in bleeding and transfusion
requirement. Tranexamic acid attaches to lysine-binding
sites on plasminogen and plasmin to inhibit binding to fi-
brinogen and fibrin. Because plasmin and plasminogen can
not bind to fibrin and fibrinogen, fibrinolysis is inhibited.10
We investigated the separate and combined hemostatic
effects of tranexamic acid, a potent antifibrinolytic agent,
and desmopressin during cardiac surgery in an effort to
determine whether the salutary effect of tranexamic acid on
desmopressin induced the fibrinolytic state.
Materials and Methods
One hundred elective coronary artery bypass operations were per-
formed between April 1999 and November 2000. Patients were
divided into 2 groups, with each group including 50 patients. The
purpose of the study was explained to all patients. Informed con-
sent was also obtained from all patients. Tables of random digits
were used for randomization of patients.11 Bleeding amount, reop-
eration, and transfusion requirement were analyzed in this
prospective randomized study. Desmopressin (0.3 µg/kg adminis-
tered intravenously over 20 minutes) was administrated in group 1
(n = 50) patients just after extracorporeal circulation and after
completion of protamine infusion. Tranexamic acid and desmo-
pressin were both administrated in group 2 (n = 50) patients before
the skin incision at a loading dose of 10 mg/kg over 30 minutes,
followed by 12 hours at 1 mg·kg–1·h–1. Desmopressin was admin-
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istrated as in group 1. Informed consent was obtained from all
patients in each group.
Patients were excluded from participation if they took warfarin
or estrogen within 10 days, had active hematuria, had a serum cre-
atinine concentration of 2 mg/dL or greater, had a personal or fam-
ily history of abnormal bleeding, or underwent intra-aortic balloon
counterpulsation. Patients receiving aspirin within 10 days of the
operation or nonsteroidal anti-inflammatory medication within 5
days of the operation were also excluded from the study. Enrolled
patients underwent coronary revascularization only. Patient demo-
graphics are summarized in Table 1.
CPB was established with a roller pump nonpulsatile flow after
anticoagulation with bovine lung heparin (3 mg/kg), and activated
clotting time was maintained for more than 480 seconds.
Membrane oxygenators (Capiox-E Terumo Corp, Tokyo, Japan)
were used in all cases. Heparin was reversed by administration of
protamine (3.5 mg/kg) at the end of the CPB period. All distal
anastomoses were performed in a single crossclamp period. The
left internal thoracic artery was used in all patients. The right inter-
nal thoracic artery was used in 19 patients, and the radial artery
was used in 56 patients in both groups. The saphenous vein was
harvested as needed. Posterior pericardiotomy was done in all
patients, as described by Mulay and coworkers.12 After routine clo-
sure of the chest, continuous suction (10 mm Hg) was applied to
drains, which were milked and stripped at 30-minute intervals to
ensure tube patency. Chest tubes were removed when the drainage
was less than 20 mL/h for 4 consecutive hours.
Hemoglobin concentration, hematocrit value, platelet count, pro-
thrombin time, activated partial thromboplastin time, fibrinogen, and
fibrin split products (FSPs) were measured before the operation and
an hour after the patients arrived in the intensive care unit.
Homologous packed red cells were administered only when the
hematocrit value fell to less than 25%. Patients received fresh frozen
plasma when excessive blood loss was accompanied by a prolonged
(>1.5 times normal values) prothrombin time. Additional protamine
was administered if the activated clotting time/control time ratio was
greater than 1.5. Platelet transfusion was used when the platelet
count fell below 40,000/mL. Shed blood was not autotransfused in
TABLE 1. Patient demographics
Group 1 (n = 50) Group 2 (n = 50)
Mean ± SD n Mean ± SD n P value
Female sex (n) 12 15 .27*
Age (y) 61 ± 7 59 ± 4 .32†
Distal anastomosis 2.3 ± 0.5 2.5 ± 0.4 .71†
Crossclamp time (min) 44 ± 7 51 ± 4 .12†
Total perfusion time (min) 56 ± 6 61 ± 5 .18†
LITA 50 50 1*
RITA 10 9 .81*
Radial artery 31 25 .19*
Saphenous vein 11 15 .26*
LITA, Left internal thoracic artery; RITA, right internal thoracic artery.
*χ2 Test was used.
†Student t test was used.
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any of the patients during the study. Reoperation was undertaken if
blood loss exceeded 500 mL for 2 consecutive hours without signs
of decreasing despite appropriate therapy.
CPB time, total operation time, amount of total chest drainage,
prevalence of reoperation for bleeding, cause of bleeding, need for
donor blood transfusion or fresh frozen plasma, and thrombocyte
suspension were recorded for all patients. The course of the blood
hemoglobin content and FSPs during the hospitalization were ana-
lyzed in each patient.
Statistical analysis was performed with SPSS software version 7.0
(SPSS Inc, Chicago, Ill). Clinical data are expressed as mean values
± SD. Differences were analyzed with the Student t test and χ2 test.
Results
No differences were found between groups 1 and 2 in patient
age, sex, crossclamp use, and CPB time. Also, the number of
bypass grafts and the number of right internal thoracic arter-
ies, left internal thoracic arteries, and radial arteries used per
patient undergoing coronary artery bypass graft operation
were not statistically different between the groups (Table 1).
Significantly less total postoperative drainage was noted in
group 2 (1010 ± 49.9 vs 623 ± 41.3 mL, P = .0001). Platelet
transfusion was required in 2 patients in both groups. The use
of banked donor blood products during the operation was sta-
tistically significant. Packed red blood cells were transfused at
2.1 ± 0.5 units per patient in group 1 versus 0.9 ± 0.3 units in
group 2 (P = .0001). Fresh frozen plasma was transfused at
1.84 ± 0.17 units per patient in group 1 versus 0.76 ± 0.14
units in group 2 (P = .0001) Transfusion requirements were
significantly lower in group 2. Only 24% of patients in group
2 required donor blood or blood products compared with 74%
of those in the isolated desmopressin (group 1) group (P =
.00001, Table 2).
There were no statistically significant differences
between the 2 groups with regard to platelet count, pro-
thrombin use, and partial thromboplastin time, but there
were statistically significant differences with regard to post-
operative fibrinogen (113 ± 56.3 mg/dL vs 167 ± 45.8
mg/dL, P = .0001), FSPs (21.2 ± 2.3 ng/mL vs 13.5 ± 3.4
ng/mL, P = .0001), and postoperative hemoglobin level (7.6
± 1.2 g/dL vs 9.1 ± 1.2 g/dL, P = .0001; Table 3). There
were also no significant differences between the groups in
postoperative hemodynamics, duration of stay in the inten-
sive care unit, and duration of postoperative hospital stay
(data not shown). One patient in each group underwent
reoperation for excessive bleeding. A sternal bleeding site
was identified. There were no instances of renal impairment
or allergic reaction to hemostatic drugs in either group.
Transient hypotension developed in 6 patients in group 1
and in 4 patients in group 2. The rate of infusion of desmo-
pressin reduced, and hypotension gradually disappeared.
Two patients (one of them in group 1) had deep venous
thrombosis during the days of hospitalization. Perioperative
myocardial infarction developed in 3 patients (one of them
in group 1), but hemodynamic instability did not develop in
these patients.
Discussion
The hemostatic defects associated with CPB are complex,
and the reasons for excessive postoperative bleeding are
multifactorial. However, qualitative and quantitative platelet
defects1,13-15 have been shown to be an important factor,
especially with CBP time.13 Contact with a synthetic sur-
face results in α-granule release, with subsequent reduced
aggregation and adhesiveness of the platelet. Although these
defects are short lived (1-2 hours), they contribute to exces-
sive blood loss and the increased use of homologous blood
and blood-component therapy.13
TABLE 2. Bleeding amount and total transfusion requirement
Group 1 Group 2 P value
Total bleeding 
amount (mL) 1010 ± 49.9 623 ± 41.3 .0001*
Fresh frozen plasma 
(units/patient) 1.84 ± 0.17 0.76 ± 0.14 .0001*
Packed red blood 
cells (units/patient) 2.1 ± 0.5 0.9 ± 0.3 .0001*
Platelets (units/patient) 0.02 0.02 1†
Patients receiving 
transfusion (%) 74 24 .00001†
Values are given as means ± SD.
*Student t test was used.
†χ2 Test was used.
TABLE 3. Hematologic values and coagulation tests
Group 1 (n = 50) Group 2 (n = 50) P value
Hemoglobin (g/dL)
Preoperative 13.2 ± 1.3 13.5 ± 1.5 .288
Postoperative 7.6 ± 1.2 9.1 ± 1.2 .0001
Platelets (109/L)
Preoperative 295 ± 75.8 267 ± 89.3 .09
Postoperative 121 ± 23.5 126 ± 34.4 .398
Fibrinogen (mg/dL)
Preoperative 356 ± 45.3 345 ± 56.2 .284
Postoperative 113 ± 56.3 167 ± 45.8 .0001
Prothrombin time (s)
Preoperative 13.2 ± 0.5 13.4 ± 1.2 .325
Postoperative 12.8 ± 0.7 13 ± 1.1 .289
Partial thromboplastin time
Preoperative 36.1 ± 4.2 35.6 ± 3.2 .504
Postoperative 38.2 ± 3.8 37 ± 2.3 .062
FSP
Preoperative 5.5 ± 2.1 5.7 ± 3.2 .725
Postoperative 21.2 ± 2.3 13.5 ± 3.4 .0001
Values are given as means ± SD. The Student t test was used in all param-
eters.
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Desmopressin acetate is one form of pharmacologic ther-
apy that may be efficacious in decreasing platelet dysfunc-
tion. Desmopressin enhances platelet effectiveness by
increasing plasma levels of high multimetric von Willebrand
factor,16 factor VIIIc, factor VIIIag,16 and other undefined
mechanisms.17 Recently, many reports about use of desmo-
pressin in cardiac surgery have been published (Table
4).4,18-26 In some of these studies, desmopressin has a salu-
tary effect on postoperative blood loss and transfusion
requirements,4,18 but mostly, transfusion requirements were
not different from those of placebo groups.19-25 LoCicero26
has pointed out that desmopressin increased both transfu-
sion requirement and blood loss. Both postoperative blood
loss (1010 ± 49.9 mL vs 623 ± 41.3 mL, P = .0001) and
transfusion requirement (74% vs 24%, P = .00001) were
significantly increased in our group 1 patients. Melissari
and coworkers8 and Küçük and colleagues9 revealed that
desmopressin transiently releases tissue-type plasminogen
activator from endothelial cells. These plasminogen activa-
tors could augment the CPB-associated fibrinolytic state.9,13
We routinely measured FSPs and noticed that FSPs statisti-
cally significantly increased in group 1 when compared with
levels in group 2 (21.2 ± 2.3 ng/mL vs 13.5 ± 3.4 ng/mL, P
Cardiopulmonary Support and Physiology Özal et al
= .0001). Postoperative fibrinogen also decreased in our
study as a result of increased fibrinolytic activity in group 1
(113 ± 56.3 mg/dL vs 167 ± 45.8 mg/dL, P = .0001). If the
fibrinolytic activity is abolished by a lysine-analogue
antifibrinolytic preparation, such as tranexamic acid,
desmopressin exerts salutary effect on platelets. Of group 2
patients (n = 50 patients), those receiving both desmo-
pressin and tranexamic acid had statistically significant
results when total blood loss (P = .0001) and total transfu-
sion requirement (P = .0001) were considered. Our reoper-
ation rate was also extremely low. We believe that it fully
depended on posterior pericardiotomy,12 which significantly
reduces the incidence of pericardial tamponade.
Both fibrinolysis and partial platelet activation during CPB
with subsequent platelet dysfunction may alter hemostasis
after CPB.9,13 Because plasmin induces platelet activation, a
potential role for lysine-analogue antifibrinolytic medications
is to block plasmin receptors on platelets inhibiting local fibri-
nolysis-induced partial platelet activation.27 Administration of
tranexamic acid before CPB is associated with preserved
platelet adenosine diphosphate and decreased bleeding after
CPB.28 We thought that tranexamic acid not only masks fibri-
nolytic activity of desmopressin but also exerts hemostatic
TABLE 4. Comparison of major clinical evaluations of desmopressin in reducing post-CPB blood loss and transfusion
requirement
Table available in print only
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effects by means of platelet preserving. The data of Horrow
and coworkers29 suggest that desmopressin-induced release of
tissue plasminogen activators plays no role in desmopressin’s
lack of hemostatic effect during cardiac surgery. Horrow and
coworkers also demonstrate that tranexamic acid decreases
the incidence of FSPs, decreases blood loss after surgery, and
decreases the likelihood of homologous blood transfusion. We
did not have an isolated tranexamic acid group, and therefore
we could not compare our results with those for isolated
tranexamic acid administration. The study by Horrow and
coworkers not only included coronary artery surgery but also
valve and congenital defect operations.
Stroke, myocardial infarction, and deep vein thrombosis
were also reported after use of hemostatic drugs. Stroke did not
develop in our study, but deep vein thrombosis in leg veins
developed in 2 patients. Deep vein thrombosis was treated with
classical therapy in the postoperative period. Perioperative
myocardial infarction developed in 3 patients (one of them in
group 1). Horrow and coworkers29 reported their stroke inci-
dence as 7.89% (3/38) in the isolated desmopressin group and
2.5% (1/40) in patients receiving both drugs.
Desmopressin significantly increases postoperative blood
loss and transfusion requirement after coronary artery bypass
surgery by releasing tissue-type plasminogen from endothelial
cells. Desmopressin and CPB-associated hyperfibrinolytic
state can be prevented by using tranexamic acid. Tranexamic
acid and desmopressin significantly reduces postoperative
blood loss and transfusion requirement.
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